Clinical Trial Update: Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of cetuximab and recombinant interleukin-12 in patients with head and neck squamous cell carcinoma that is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• recombinant interleukin-12 (interleukin-12)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2017-08-31